Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates

分组1 - Rigel Pharmaceuticals reported quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share, but showing an increase from $0.8 per share a year ago, resulting in an earnings surprise of -14.29% [1] - The company posted revenues of $69.8 million for the quarter ended December 2025, which aligns with the Zacks Consensus Estimate and represents a year-over-year increase from $57.6 million [2] - Rigel has surpassed consensus EPS estimates three times over the last four quarters, indicating a generally positive trend in earnings performance [2] 分组2 - The stock has underperformed the market, losing about 19.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.90 on revenues of $61.67 million, and for the current fiscal year, it is $3.97 on revenues of $285.45 million [7] - The Medical - Drugs industry, to which Rigel belongs, is currently in the bottom 45% of the Zacks industry rankings, suggesting potential challenges ahead [8]